Category: Bacterial Pneumonia

Bacterial Pneumonia – Bacterial.org

FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

GAITHERSBURG, Md.–(BUSINESS WIRE[1])–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat multi-drug resistant bacterial infectious diseases, today announced clearance by the U.S. Food and Drug Administration (FDA) of the company’s Expanded Access IND for PhageBank™ treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus in COVID-19 patients. “The FDA’s decision...

READ MORE FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

Monoclonal Antibody-Based Therapies for Bacterial Infections

Abstract Purpose of review This review highlights recent developments in the development of monoclonal antibodies to treat bacterial disease, including preclinical advances and the status of current clinical trials. Recent Findings Monoclonal antibody (mAb) therapy is becoming increasingly promising in the infectious disease field. Though bacterial exotoxins continue to be a mainstay of mAb targets, searches for protein targets on...

READ MORE Monoclonal Antibody-Based Therapies for Bacterial Infections